scholarly journals Heterologous expression of human KGF/FGF7 (Keratinocyte growth factor) in Pichia pastoris

Author(s):  
Thư Anh Nguyễn Phạm ◽  
Trang Thị Thuỳ Nguyễn ◽  
Nghĩa Hiếu Nguyễn ◽  
Thao Thi Phuong Dang

Keratinocyte Growth Factor (KGF) is a paracrine-acting and epithelium-specific growth factor produced by cells of mesenchymal origin, play an important role in promoting proliferation, differentiation, motility of epithelial cells and stimulating regeneration of damaged epithelial tissues. Recent studies indicated that recombinant KGF is produced in many different expression systems such as bacteria, insect cells, plant and mammalian cells. However, KGF’s yields obtained from these systems is low and production’s cost is high especially in mammalian cells. In this study, the yeast Pichia pastoris was chosen as a host for KGF expression through induction of methanol by promoter AOX on pPICzαA vector system. The results demonstrated that the Pichia pastoris X33:kgf  transformants secreted KGF directly into BMMY medium after inducing by 0.5% methanol. The recombinant protein was purified by heparin affinity chromatography with the yield of 1.35 mg/l and the purity of 99.89% showed by SDS-PAGE. In addition, MTT assay showed the purified recombinant KGF had a proliferation effect on A549 cell line since A549 known as a cell has KGF’s receptor.

2007 ◽  
Vol 132 (1) ◽  
pp. 44-48 ◽  
Author(s):  
Yanchun Wang ◽  
Shengling Yuan ◽  
Peng Wang ◽  
Xiangxin Liu ◽  
Dewen Zhan ◽  
...  

Blood ◽  
2006 ◽  
Vol 109 (6) ◽  
pp. 2529-2537 ◽  
Author(s):  
Dullei Min ◽  
Angela Panoskaltsis-Mortari ◽  
Makoto Kuro-o ◽  
Georg A. Holländer ◽  
Bruce R. Blazar ◽  
...  

Abstract Age-related thymopoietic insufficiency has been proposed to be related to either defects in lymphohematopoietic progenitors or the thymic microenvironment. In this study, we examined whether keratinocyte growth factor (KGF), an epithelial cell–specific growth factor, could increase thymopoietic capacity in aged mice by restoration of the function of thymic epithelial cells (TECs). The thymic cellularity in KGF-treated aged mice increased about 4-fold compared to placebo-treated mice, resulting in an equivalent thymic cellularity to young mice. Enhanced thymopoiesis was maintained for about 2 months after a single course of KGF, and sustained improvement was achieved by administration of monthly courses of KGF. With the enhanced thymopoiesis after KGF treatment, the number of naive CD4 T cells in the periphery and T-cell–dependent antibody production improved in aged mice. KGF induced increased numbers of TECs and intrathymic interleukin-7 (IL-7) production and reorganization of cortical and medullary architecture. Furthermore, KGF enhanced thymopoiesis and normalized TEC organization in klotho (kl/kl) mice, a model of premature degeneration and aging, which displays thymopoietic defects. The result suggests that TEC damage is pathophysiologically important in thymic aging, and KGF therapy may be clinically useful in improving thymopoiesis and immune function in the elderly.


2001 ◽  
Vol 120 (5) ◽  
pp. A695-A695
Author(s):  
M RUEHL ◽  
I SCHOENFELDER ◽  
R FARNDALE ◽  
G KNIGHT ◽  
R SOMASUNDARAM ◽  
...  

2005 ◽  
Vol 43 (05) ◽  
Author(s):  
M Mühlbauer ◽  
T Amann ◽  
J Schölmerich ◽  
A Bosserhoff ◽  
C Hellerbrand

Diabetes ◽  
1997 ◽  
Vol 46 (1) ◽  
pp. 138-142 ◽  
Author(s):  
R. Morishita ◽  
S. Nakamura ◽  
Y. Nakamura ◽  
M. Aoki ◽  
A. Moriguchi ◽  
...  

2020 ◽  
Vol 51 (3) ◽  
pp. 172-178
Author(s):  
Natalia Bartoszewicz ◽  
Krzysztof Czyżewski ◽  
Robert Dębski ◽  
Anna Krenska ◽  
Ewa Demidowicz ◽  
...  

AbstractIntroductionOral mucositis is regarded by patients as one of the worst and debilitating complications of conditioning and hematopoietic cell transplantation (HCT). Prevention of mucositis is one of the priorities of supportive therapy during and after conditioning.ObjectivesThe primary objective of the study was the analysis of efficacy of keratinocyte growth factor (KGF, palifermin) used in prophylaxis of oral mucositis in patients undergoing allo-HCT. The secondary objectives of the study included the analysis of the influence of palifermin on clinical course of oral mucositis and early transplant outcomes, as well as analysis of the contraindications of palifermin in patients undergoing allo-HCT.Patients and methodsA total number of 253 allo-HCT performed between 2003 and 2018 in patients aged 0–19 years in a single center were analyzed. Overall, in 161 HCTs, palifermin was administered.ResultsPatients receiving KGF were transplanted earlier in the context of calendar year, and more often received ATG, mainly due to the higher rate of unrelated donor transplants. Allo-HCT patients who were administered palifermin had shorter time of mucositis (median: 9 vs. 13 days, p < 0.001), lower mucositis grade (median: 2° vs. 3°; p < 0.001), shorter period of total parenteral nutrition (median: 19 vs. 22 days; p = 0.018), and lower incidence of episodes of febrile neutropenia (median: 39.1% vs. 83.1%; p < 0.001).ConclusionsThe use of palifermin has decreased duration and severity of oral mucositis in children after allo-HCT. Palifermin is a safe and well-tolerated compound in children undergoing allo-HCT.


Sign in / Sign up

Export Citation Format

Share Document